Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Shares Outstanding (Diluted Average): 2020-2022

Historic Shares Outstanding (Diluted Average) for Tg Therapeutics (TGTX) over the last 3 years, with Dec 2022 value amounting to $135.4 million.

  • Tg Therapeutics' Shares Outstanding (Diluted Average) rose 4.99% to $141.5 million in Q2 2023 from the same period last year, while for Jun 2023 it was $141.5 million, marking a year-over-year increase of 4.99%. This contributed to the annual value of $135.4 million for FY2022, which is 2.41% up from last year.
  • Tg Therapeutics' Shares Outstanding (Diluted Average) amounted to $135.4 million in FY2022, which was up 2.41% from $132.2 million recorded in FY2021.
  • In the past 5 years, Tg Therapeutics' Shares Outstanding (Diluted Average) ranged from a high of $135.4 million in FY2022 and a low of $115.3 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $127.7 million, with a median of $132.2 million in 2021.
  • Data for Tg Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY rose of 14.64% (in 2021) over the last 5 years.
  • Over the past 3 years, Tg Therapeutics' Shares Outstanding (Diluted Average) (Yearly) stood at $115.3 million in 2020, then increased by 14.64% to $132.2 million in 2021, then rose by 2.41% to $135.4 million in 2022.